Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers

Abstract

Like BRCA2, MAGEC3 is an ovarian cancer predisposition gene that has been shown to have prognostic significance in ovarian cancer patients. Despite the clinical significance of each gene, no studies have been conducted to assess the clinical significance of their combined expression. We therefore sought to determine the relationship between MAGEC3 and BRCA2 expression in ovarian cancer and their association with patient characteristics and outcomes. Immunohistochemical staining was quantitated on tumor microarrays of human tumor samples obtained from 357 patients with epithelial ovarian cancer to ascertain BRCA2 expression levels. In conjunction with our previously published MAGEC3 expression data, we observed a weak inverse correlation of MAGEC3 with BRCA2 expression (r = −0.15; p < 0.05) in cases with full-length BRCA2. Patients with optimal cytoreduction, loss of MAGEC3, and detectable BRCA2 expression had better overall (median OS: 127.9 vs. 65.3 months, p = 0.035) and progression-free (median PFS: 85.3 vs. 18.8 months, p = 0.002) survival compared to patients that were BRCA2 expressors with MAGEC3 normal levels. Our results suggest that combined expression of MAGEC3 and BRCA2 serves as a better predictor of prognosis than each marker alone.

The Impact of BRCA1 Expression on Survival Status in Ovarian Serous Carcinoma of Egyptian Patients

“…Multivariate analysis confirmed an independent prognostic value of the BRCAness phenotype among the high-grade serous carcinoma subgroup, hazard ratio 0.65 (95% CI 0.47 to 0.92), p=0.014. Omole et al, (2022), stated that BRCA is an ovarian cancer predisposition gene that has been shown to have prognostic significance. They found a relationship between BRCA expression and patient outcomes.…”

Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches

“…They are used for the detection of gene and/or protein expression and mutation detection. For example, immunohistochemical staining and/or CSC-markers-based cell sorting revealed the abundance and CSC distribution between normal and cancer tissue at different stages and clinical outcomes [ 405 , 406 , 407 , 408 ].…”